Fox Run Management, L.L.C. Immuno Gen, Inc. Transaction History

Fox Run Management, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$4.55 - $6.31 $43,593 - $60,456	-9,581 Reduced 43.85%	12,270 $60,000
Q3 2022 Nov 07, 2022	BUY	$4.48 - $6.47 $97,892 - $141,375	21,851 New	21,851 $104,000
Q1 2022 May 10, 2022	SELL	$4.26 - $7.48 $44,176 - $77,567	-10,370 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$4.75 - $7.5 $49,257 - $77,775	10,370 New	10,370 $77,000
Q1 2019 Oct 17, 2019	SELL	$2.41 - $5.91 $36,511 - $89,536	-15,150 Closed	0 $0
Q4 2018 Jan 15, 2019	BUY	$3.94 - $9.7 $59,691 - $146,955	15,150 New	15,150 $73,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.